NCT05390515PHASE4Recruiting

Psoriatic Immune Response to Tildrakizumab

University of California, San Francisco

Start Date

9/1/2022

Completion Date

9/1/2028

Summary

This study aims to assess cutaneous and blood immune cell function of patients with psoriasis before and after initiation of treatment with the IL23 blocker, tildrakizumab.

Detailed Description

This is a one-arm, open-label study to examine the effect of Tildrakizumab on cutaneous and blood immune cells of psoriatic patients. Ten subjects with moderate to severe psoriasis will be enrolled. Biopsy and blood samples will be collected before and during treatment and undergo molecular profiling to assess for tildrakizumab-corrected signatures.

Eligibility Criteria

Age Range: 18 years to 75 years

Inclusion Criteria: * 18 years of age or older * Patients with moderate-severe psoriasis or \> 5% body surface area affected. Exclusion Criteria: * taking systemic immunosuppressives in the last 4 weeks * pregnancy * severe immunodeficiency (either from genetic or infectious causes). * tuberculosis or other active serious infection * active systemic malignancy. * breast-feeding * Presence of a condition or abnormality that in the opinion of the Investigator would compromise the safety of the patient or the quality of the data.

Interventions

DRUG

Tildrakizumab Prefilled Syringe

Interested in This Trial?

Contact the trial locations directly using the information below to learn more about enrollment.

Expressing interest lets you review the study and consent before we connect you with the research site.

Conditions

Psoriasis Vulgaris

Locations

University of California, San Francisco

San Francisco, California 94115

United States